Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Expires | Type | Strike | OI | Change | Percent |
---|---|---|---|---|---|
06/20/2025 | PUT | $290.00 | 3,500 | +1,200 | +52.17% |
06/20/2025 | CALL | $280.00 | 2,087 | +716 | +52.22% |
07/18/2025 | CALL | $260.00 | 814 | +651 | +399.39% |
06/20/2025 | PUT | $250.00 | 1,712 | +360 | +26.63% |
06/20/2025 | CALL | $270.00 | 776 | +334 | +75.57% |
06/20/2025 | PUT | $260.00 | 1,561 | +244 | +18.53% |
05/16/2025 | CALL | $260.00 | 10 | -164 | -94.25% |
05/16/2025 | CALL | $262.50 | 0 | -200 | -100.00% |
06/20/2025 | CALL | $290.00 | 2,000 | -300 | -13.04% |
05/16/2025 | CALL | $267.50 | 17 | -413 | -96.05% |
05/16/2025 | CALL | $270.00 | 156 | -418 | -72.82% |
05/16/2025 | CALL | $265.00 | 16 | -635 | -97.54% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Name | Pct Held | Shares | Total |
---|---|---|---|
Vanguard Total Stock Market Index Fund | 3.04% | 16.22M | 3.66B |
Vanguard 500 Index Fund | 2.31% | 12.33M | 2.78B |
Vanguard/Primecap Fund | 1.71% | 9.12M | 2.06B |
Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 1.31% | 7.02M | 1.58B |
Schwab Strategic Tr-Schwab U.S. Dividend Equity ETF | 1.25% | 6.7M | 1.51B |
Fidelity 500 Index Fund | 1.09% | 5.85M | 1.32B |
SPDR S&P 500 ETF Trust | 1.08% | 5.78M | 1.3B |
SPDR Dow Jones Industrial Average ETF | 1.05% | 5.6M | 1.26B |
iShares Core S&P 500 ETF | 0.89% | 4.76M | 1.07B |
Capital Income Builder, Inc. | 0.89% | 4.74M | 1.07B |
Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI
05/08 11:00 am
GlobeNewswire Inc.
Read moreAmgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data
05/02 03:57 pm
Benzinga
Read moreLiver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research®
05/02 10:00 am
GlobeNewswire Inc.
Read moreBeat the Nasdaq With This Cash-Gushing Dividend Stock
05/01 08:30 am
The Motley Fool
Read more4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
04/26 06:05 pm
The Motley Fool
Read moreWhy Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
04/22 05:37 pm
The Motley Fool
Read more3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
04/22 09:53 am
The Motley Fool
Read more[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
04/14 10:00 am
GlobeNewswire Inc.
Read moreBiopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline
04/10 05:59 am
GlobeNewswire Inc.
Read moreMinimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
04/08 04:48 am
GlobeNewswire Inc.
Read more3 Dividend Stocks to Buy and Hold for the Next Decade
04/06 06:44 am
The Motley Fool
Read more2 Dividend Stocks to Buy Hand Over Fist in April
04/05 08:30 am
The Motley Fool
Read moreNasdaq 100 Enters Bear Market, Dow In Correction Territory, Traders Await Fed Chair Powell's Remarks
04/04 10:56 am
Benzinga
Read moreFDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder
04/04 10:30 am
Benzinga
Read moreWhy Pharma and Biotech Stocks Got Thrashed on Tuesday
03/25 06:47 pm
The Motley Fool
Read morePharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
03/21 12:31 pm
Benzinga
Read morePrediction: These 2 Stocks Will Outperform the Market Through 2030
03/18 09:53 am
The Motley Fool
Read more5 Reasons the Schwab U.S. Dividend Equity ETF Is a Long-Term Buy for 2030 and Beyond
03/17 07:45 am
The Motley Fool
Read moreBioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - Report by Transparency Market Research, Inc.
03/13 06:00 pm
GlobeNewswire Inc.
Read moreBispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide
03/12 08:48 am
GlobeNewswire Inc.
Read moreIs Eli Lilly Stock a Buy?
03/11 04:10 am
The Motley Fool
Read moreAmgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
03/10 12:50 pm
Benzinga
Read more1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
03/09 06:20 am
The Motley Fool
Read more3 Magnificent Growth Stocks to Buy in March
03/08 11:41 am
The Motley Fool
Read moreInternational Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
03/01 09:45 am
GlobeNewswire Inc.
Read moreThis Could Be the Best GLP-1 Stock to Buy in 2025
02/28 09:45 am
The Motley Fool
Read moreOncology Breakthroughs: How Cancer Research Is Advancing in 2025
02/27 11:04 am
Benzinga
Read moreThese 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?
02/25 05:53 am
The Motley Fool
Read moreTALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight
02/24 02:00 pm
GlobeNewswire Inc.
Read moreQuestex’s Fierce Pharma Unveils the Conference Program for the Inaugural Fierce Pharma Engage, Over 100 Speakers Confirmed to Deliver Unparalleled Education
02/24 11:00 am
GlobeNewswire Inc.
Read moreWant Decades of Passive Income? Buy This ETF and Hold It Forever.
02/18 07:15 am
The Motley Fool
Read moreInvesting $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
02/10 07:15 am
The Motley Fool
Read more3 Fabulous Dividend Stocks to Buy in February
02/09 03:30 pm
The Motley Fool
Read moreParesthesia Treatment Market Outlook: USD 8.0 Billion by 2034, Growing with an Aging Population and Rising Healthcare Expenditures | Analysis by TMR
02/07 12:39 pm
GlobeNewswire Inc.
Read moreAmgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
02/05 01:21 pm
Benzinga
Read moreAplastic Anemia Global Clinical Trials Review 2024 | Now Available
02/04 12:00 pm
GlobeNewswire Inc.
Read moreRecombinant Chemicals Market to Reach US$ 6.7 Bn by 2034, Driven by Rising Demand for Protein-Based Vaccines & Genetic Disorder Treatments – TMR Analysis
01/31 10:00 am
GlobeNewswire Inc.
Read moreBiological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer
01/27 11:49 am
GlobeNewswire Inc.
Read moreThese Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
01/25 07:17 am
The Motley Fool
Read moreDelta-like Ligand 3 (DLL3) Targeted Therapies Market Research 2025: 1 Drug, Imdelltra (Tarlatamab) Available / 10 Drugs by Company, Indication and Phase / Approved Drug Dosage, Sales & Pricing Insight
01/23 08:51 am
GlobeNewswire Inc.
Read moreCan the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
01/21 06:34 am
The Motley Fool
Read moreFDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
01/17 01:11 pm
Benzinga
Read moreEngineered Multispecific Antibodies Innovation Research Report 2024: Patent Trends Show a Noticeable Surge in 2023 with Regeneron, Roche, and Amgen Emerging as the Top Patent Filers
01/17 05:57 am
GlobeNewswire Inc.
Read more7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - Synergistic Rise of Pumps, CGMs, and Ultra-rapid-acting Insulins in T1D Management
01/17 05:53 am
GlobeNewswire Inc.
Read moreGlobal Pharma & Biotech CRM Software Market To Surpass Valuation of US$ 20.0 Billion by 2033 | Astute Analytica
01/17 04:30 am
GlobeNewswire Inc.
Read moreGot $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
01/14 08:25 am
The Motley Fool
Read moreObesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
01/09 03:12 pm
Benzinga
Read moreNUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries
01/09 11:53 am
GlobeNewswire Inc.
Read moreAlzheimer's Disease Diagnostics Research Report 2024-2034: Global Market to Reach $27.87 Billion - Focus on Cost-Effective Alzheimer's Diagnostics Gaining Momentum
01/09 11:48 am
GlobeNewswire Inc.
Read moreImmunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth Potential
01/09 05:52 am
GlobeNewswire Inc.
Read more